☆ 4.6 Article

P415 The anti-IL-23/IL-12 agent Ustekinumab is an effective and safe induction therapy in patients with Crohn’s disease refractory or intolerant to anti-TNF: a multicentre Italian study

Journal of Crohns & Colitis (2020)

Get Full Text
Add to Collection

Journal

Journal of Crohns & Colitis
Volume 14, Issue Supplement_1, Pages S379-S379

Publisher

Oxford University Press (OUP)
DOI: 10.1093/ecco-jcc/jjz203.544

Keywords

-

Categories

Gastroenterology & Hepatology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.